Hit enter to search or ESC to close

Investor Centre

Alterity Therapeutics is developing best-in-class therapies to treat neurodegenerative disease.

The Company was incorporated in 1997 in Melbourne, Australia and listed on the Australian Securities Exchange in 2000 and NASDAQ in 2002

The company operates under the tickers ASX: ATH and NASDAQ: ATHE.

Investment Highlights

  • Strong and highly experienced board and management team with significant R&D and commercialisation experience including 3 drug approvals by US FDA.
  • ATH434 is a novel drug candidate targeting key proteins implicated in neurodegeneration of Parkinson’s disease and atypical parkinsonism.
  • ATH434 has completed its Phase 1 clinical trial program.
  • First therapeutic target selected – Multiple System Atrophy (MSA), a form of atypical parkinsonism, is a devastating disease with no approved treatments.
  • FDA Orphan Drug designation in the U.S. and EU for ATH434 for the treatment of MSA received.
  • Significant market potential in MSA – estimated peak sales of US$725M.

Investor Resources

Company presentations

Analyst Reports

ASX Announcements


Financial reports


Corporate governance


Dr David Stamler appointed CEO

The Board of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is pleased to announce the appointment of

Read More
Quarterly Cash Flow Report

Highlights: Completion of Phase 1 Clinical Trial; PBT434 found to be safe and well-tolerated; clinically tested doses achieve concentrations

Read More

Receive news from Alterity Therapeutics